The IMpassion 050 (NCT03726879) was the first phase III trial to compare the combination of atezolizumab with a neoadjuvant therapy based on dose-dense anthracycline, taxane, trastuzumab, and pertuzumab, vs. the same regimen without atezolizumab, in patients with HER2-positive early breast cancer at high risk (defined as tumor size of more than 2 cm and node-positive disease) [49] (Table 1). This evidence concerns the gene ERBB2 and neoplasm.